BeyondSpring Inc. reported that James Tonra, Ph.D. resigned as its Chief Scientific Officer, effective March 15, 2021, to pursue an opportunity with a company focused on infectious diseases research and development. Dr. Tonra was instrumental in helping to elucidate Plinabulin’s immune mechanism of action. He will continue as a scientific advisor for the Company for an effective and timely transition of his responsibilities to G. Kenneth Lloyd, Ph.D., who will immediately resume the position of Chief Scientific Officer. Dr. Lloyd held the position of Chief Scientific Officer of the Company prior to serving as Chief Scientific Officer Emeritus and Senior Advisor to the Company.